PARIS ( TheStreet) -- Sanofi-Aventis ( SNY) shares fell almost 5% Friday after its cancer drug iniparib didn't meet primary endpoints of overall survival and progression-free survival for breast cancer patients. The Phase III clinical trial evaluated in patients with metastatic triple-negative breast cancer. The study enrolled 519 women with the cancer from 109 sites in the United States. Patients were randomized to receive a standard chemotherapy regimen (gemcitabine and carboplatin) with iniparib to one without the drug. Sanofi-Aventis, the French drugmaker, said there wasn't a significant difference between the two regimens. -- Written by Joseph Woelfel >To contact the writer of this article, click here: Joseph Woelfel >To submit a news tip, send an email to: email@example.com.